SESSION TITLE: Treatment of IPF
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Monday, October 24, 2016 at 07:30 AM - 08:30 AM
PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, unpredictable and often rapidly fatal fibrosing lung disease requiring early intervention to improve outcomes. Patients with IPF whose percent predicted forced vital capacity (%FVC) was < 50% or percent predicted diffusing capacity for carbon monoxide (%DLCO) was < 35% were excluded from the CAPACITY Phase III trials. Therefore, data on such patients in controlled clinical studies are lacking to inform clinical practice. The objective of this analysis was to assess pirfenidone benefits in this subgroup of patients with more severe lung function impairment.